Loading...

ALLR ALLARITY THERAPEUTICS INC Capital Structure Changes 8-K Filing

LLRT

LLR

ALLARITY THERAPEUTICS INC

(ALLR)

2024 8-K

Show Summary

Show Summary

Strategic Alliances

Product Expansion

Investor Meetings

Financial Statements

Investor Meetings

Financial Results

Trading Investigation

Clinical Data Release

Trial Announcement

Share Repurchase

Lawsuit Dismissed

FDA Protocol Announcement

Clinical Trial Expansion

Corporate Update

Financial Results

Patent Announcement

Nasdaq Compliance

Management Appointment

Clinical Trial Update

Management Changes

Stock Split Update

Stock Split Approval

SEC Investigation

Notice from Nasdaq

Clinical Trial Update

Management Services Agreement

Amendment to Form 8-K/A

Agreement and Compliance

Financial Results Announcement

Capital Structure Simplific...

Compliance and Withdrawal

Regulation FD Disclosure

Compliance Extension

Reverse Stock Split

Reverse Stock Split

Strategic Pivot Announcement

Compliance Extension

Agreement for Stock Sales

Entry into Material Definit...

Earnings Report

Termination of Chief Medica...

Amendment to Senior Convert...

Agreement and Note Issuance

Termination of License Agre...

Amendment to Securities Pur...

Securities Purchase Agreeme...

Management Changes

Presentation Slides

Corporate Presentation

Capital Structure Change

Agreement with Warrant Holders

Resignation and Appointment

Appointment of Directors

Nasdaq Listing Qualifications

New Product Testing

Secured Note Purchase Agree...

Reverse Stock Split

Special Meeting Approval

Adjournment of Special Meeting

Agreement Amendments

Public Offering

Public Offering

Agreement Amendment

Regulation FD Disclosure

Reverse Stock Split

Amendment to Certificate of...

Clinical Study Announcement

Securities Purchase Agreement

Agreement Modification and ...

Resignation of Directors an...

Employment Agreements

External Links:

Allarity Therapeutics, Inc. raised approximately $3.15 million by selling 35,000 shares of Series A Convertible Redeemable Preferred Stock at $90 each, and extended its license agreement with Eisai for Stenoparib, with a deadline for a Phase 2 Clinic

AI Assistant

ALLARITY THERAPEUTICS INC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.